IDOV-Immune

AXP000110.1 · Oncolytic virus

Platform
vaccinia virus
Originator
ViroMissile
Sponsor
ViroMissile

Names

NameTypeSource
IDOV-Immunepreferred name, codecurator, ctgov

Virus

Role
Oncolytic
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Replication
conditionally replicating
Modifications
not described in the registration
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07656090Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid TumorsEnrolling by invitationEarly phase 12025-12-182027-10-3119Cancer
NCT06910657IDOV-Immune for Advanced Solid TumorsRecruitingPhase 12025-08-252027-01-3178Adrenal Gland Tumors; Bladder Cancer; Breast Cancer; Cervical Cancers; Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancers; Hepatocellular Carcinoma; Lung Cancer; Melanoma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Renal Cell Carcinoma; Sarcoma

Recent changes

No changes recorded in its trials yet.

Notes

First-in-human phase 1 oncolytic vaccinia (NCT06910657, recruiting since April 2025). The related ViroMissile candidate IDOV-SAFE is a separate program on the same platform.

How to cite

IDOV-Immune (AXP000110.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000110.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.